Therapeutics to prevent age-related disease and extend healthy lifespan.
For the first time in human history the diseases that come as a consequence of simply getting older - such as cancer, heart attacks, stroke, and dementia - outweigh infectious disease as mankind's largest killers. New insights into the basic biology of aging, the major cause of all of these conditions, have led to multiple new approaches for fighting today's most deadly diseases.
Scientists are already creating new therapies to treat, delay, or even prevent these terrible diseases, allowing people to live healthier, longer lives. Apollo helps scientists and entrepreneurs build biotech companies with innovative strategic pathways to bring the first real medicines treating the damage of aging to patients.
We take the long view in creating the next generation of medicines. If an invention or therapy is just becoming ready to be accelerated to the clinic, Apollo serves as a strategic partner to scientists, helping them take their first steps as a biotechnology company. We help build great teams and leverage our network in the scientific and entrepreneurial communities to make sure our companies succeed.
Discoveries in aging biology are ready for acceleration to the clinic, where they can treat age-related disease and extend lifespan.
In the past decade, scientists have confirmed our understanding of the reasons we age at the molecular level.
Click on each type of aging damage to show more.
Apollo identifies the best science and helps entrepreneurs turn great discoveries into great companies.
Develop pharmaceuticals to mimic successful strategies for delaying aging.
Reverse the damage that accumulates with age and leads to tissue dysfunction.
Replace dysfunctional aging tissues with new, healthy ones.
Bioinformatics and diagnostic tools to make new discoveries about aging.
Clinical supplement or nutrition products to slow aging.
Pharmaceuticals for treating age-related diseases.
Advanced therapeutics for age-related damage.
Lean and flexible drug development models to maximize capital efficiency of start-ups.
Enter clinical trials for existing indications with clear regulatory paths.
Work with pharma, regulators, and insurers to preventatively treat the damage of aging.
James was only sixteen when he decided he would dedicate his life to preventing the diseases of age. He has been a scientist, entrepreneur, and advisor to biotechs and pharma companies, always with a specialization for developing new classes of therapeutics. James founded Apollo to support biotech entrepreneurs strategically, scientifically, and financially as they create the next generation of medicines.
Before Apollo James was a consultant for McKinsey and Company's biotech and pharma practice in New York, where he specialized in biotech entrepreneurship, drug launches for regenerative medicines, and R&D pipeline analysis. He received his PhD from the University of Texas Southwestern Medical Center in Dallas, where he was a National Science Foundation Fellow and worked on the basic biology of stem cells and improving gene therapies. He founded his first company, Genotyp, at 21 to overhaul hands-on science education in the US. Genotyp's innovative biotech equipment leasing model and instructor training earned it the approval of the White House and the National Institutes of Health. It became the first biotech company to receive funding through Kickstarter.com. He received a BA with special honors from the University of Chicago, where he studied immunology.
Nils is a serial entrepreneur and company builder with a long-standing passion for health and biomedicine. At Apollo, Nils brings deal making skills, his impeccable business sense, and his expertise in growing early stage startups.
Nils founded company builder and investor TruVenturo in 2010, and he has taken part in over 30 financing rounds as an investor or co-founder among the companies he has cofounded. Of these, three have attained valuations over $100M, having attracted capital from top venture capital companies such as Insight Venture Partners, Highland Capital, and Harbourvest. Nils sits on the boards of multiple companies in his portfolio, helping to push them rapidly towards inflection points by focusing his teams towards only those activities that generate shareholder value. Nils has studied business in Hamburg and at UC Santa Barbara (UCSB) in California. He also completed the EO Entrepreneurial Master's Program at MIT.
Ole is an HR expert focusing on team building and hiring in hyper-growth phases. At Apollo he provides value to portfolio companies regarding their strategic HR needs and support them in recruiting and building up excellent teams.
Ole founded CareerTeam, a headhunting agency focused on digital experts. With a headcount of over 100 employees and offices in Hamburg, Berlin and Zurich, CareerTeam helps medium-sized companies and corporates to built up digital teams. Furthermore, since 2011 Ole has built up companies with TruVenturo as a partner and board member in several companies. Before he became an entrepreneur, Ole studied economics at the University of Cologne, with emphasis on business psychology and the strategic interaction on markets. He continued this course by finishing his Ph.D. with distinction at the Universities of Cologne and California, Berkeley, as the youngest and fastest-finishing postgraduate in his faculty.
Alexandra has always considered her life goal to contribute to developing and advancing novel therapies, particularly against age-related diseases. With Apollo she will leverage her scientific and strategic expertise to support new ventures in the development of groundbreaking therapies.
Before Apollo Alexandra was a consultant with The Boston Consulting Group in Munich, where she specialized in buy- and sell-side asset valuations for biotechnology companies and biopharma portfolio strategy. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmacology and toxicology.
Harvey is working on the meaningful and future focused topic of health and biomedicine to make a difference. At Apollo, Harvey combines his entrepreneurial drive and enthusiasm for finance to assess business opportunities and assist portfolio companies with strategy and business development.
Before joining Apollo, Harvey worked at the investment bank Lazard, where he conducted M&A activities on both buy and sell side mandates. He was also one of the first employees at the FinTech startup N26, where he was responsible for talent acquisition and setting up the customer support function. He further deepened his data and business analytics skills leading a KPI and transparency initiative at the professional networking platform Xing. Harvey holds a degree in International Business with a major in Finance from Maastricht University.